Pancreatic Ductal Adenocarcinoma (PDAC)2026-05-05

PDAC Clinical Trial Indication Mapping: Competitive Landscape 2026

Indication Classification Across Five Key Clinical Programs

Pancreatic ductal adenocarcinoma (PDAC) is one of the most heterogeneous and clinically complex solid tumor indications, with meaningful variation across disease stage, line of therapy, treatment backbone, and biomarker subgroup. As the PDAC clinical trial landscape has expanded, driven by advances in RAS-targeted therapy, DNA damage response, and tumor microenvironment biology, accurate indication mapping has become essential for understanding where each program competes and which patient populations are being addressed.

Overview

This is an abbreviated sample report for a mapping of key PDAC clinical trials to their precise indications within the treatment landscape. While a small sample of six PDAC trials are covered (RASolute 303, RASolute 302, OPTIMIZE-1, PRISM-1, APOLLO, and MountainTAP-30), a complete report would map indications across the much broader set of active PDAC clinical trials. The goal is demonstrating accurate classification of the precise target indication for each program, including disease stage, line of therapy, treatment regimen, and biomarker subgroup to determine where each therapy may fall in the treatment landscape.

Trial Indication Mapping

Trial	Target Indication
RASolute 303 Daraxonrasib · Revolution Medicines · Phase 3	First line metastatic PDAC patients with RAS mutation
RASolute 302 Daraxonrasib · Revolution Medicines · Phase 3	Second line metastatic PDAC patients with RAS mutation
OPTIMIZE-1 Mitazalimab · Alligator Bioscience · Phase 1/2	First line metastatic PDAC patients (all-comers)
PRISM-1 Quemliclustat · Arcus Biosciences · Phase 3	First line metastatic PDAC patients (all-comers)
APOLLO Olaparib · NCI (AstraZeneca therapy) · Phase 2	Adjuvant post-resection localized/resectable pancreatic cancer patients with BRCA1, BRCA2, or PALB2 mutation (excluding neuroendocrine tumors)
MountainTAP-30 BMS-986504 · Bristol-Myers Squibb · Phase 2/3	First line metastatic PDAC patients with MTAP deletion or MTAP loss

Indication Matrix

Hover over any trial to see full target indication details.

Adjuvant

Metastatic

Locally Advanced

Resected

Methodology

Classification Framework

Trial indications were classified through review of trial description, inclusion / exclusion criteria, and contextual knowledge on disease and treatment staging using the most recent NCCN PDAC treatment guidelines. Disease stage and line of therapy assignments were derived from the requirements stated in the trial description and eligibility criteria.

Human Reasoning Layer

As an expert-in-the-loop quality assurance layer, indication mapping was reviewed by the Inflection Labs team for accuracy. The Olaparib APOLLO trial is a clear example of the risks of incorrect mapping: the trial's metadata places it under pancreatic cancer broadly, but review of the inclusion criteria confirms it targets a surgically resectable population in the adjuvant post-resection setting. Accurate assessment of each trial in the treatment landscape requires a combination of (1) providing LLM agents with necessary contextual knowledge (e.g., NCCN guidelines) and guiding reasoning questions (2) building a system with additional layers for output review to achieve high accuracy and precision and (3) human-in-the-loop review to verify logic behind competitive intelligence data extraction and synthesis.

Didn't find the data you were looking for?

Let us know what we missed.